Charles River Laboratories International, Inc. CRL

NYSE · Healthcare · Medical - Diagnostics & Research

$314.32

Close on Fri, 20 Nov 2026 · market value $15.1B

What the price is betting on

Priced for a lot to go right

At $314, the price assumes revenue grows about 21% a year for five years, from $4B to about $9B by FY2030. That is about six times what analysts expect for the next two years and well above the company's own last three years.

The price assumes21%
Analysts, next two years3.3%
Last 3 years−1.4%

Revenue growth a year. The price figure comes from a reverse DCF at a 10% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than CRL? Check up to 5 of your stocks at once, free, no account.

0$2.5B$5B$7.5B$10B$4B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$118

Base

$132

Bull

$146

Today $314

  • Bear $118. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $132. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $146. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$4.2B$3.9B, below the path
  3. FY2027$5.1B$4.1B, below the path
  4. FY2028$6.1B$4.3B, below the path
  5. FY2029$7.4B$4.6B, below the path
  6. FY2030$9B$5.1B, below the path

Each year's revenue at 21% growth from $4B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Diagnostics & Research · listed on NYSE

Revenue, FY2025
$4B
Growth, 3 years a year
−1.4%
Cash margin
13%
Net debt
$2.9B
Shares, 3-year change
−3.6%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.